Table 2.
Patient characteristics in the high‐BSA (BSA ≥ 1.50 m2) group
| N (%) | P | ||
|---|---|---|---|
| Characteristics | BSA < 1.5 | BSA ≥ 1.5 | |
| Gender | < 0.001 | ||
| Male | 2 (13) | 14 (87) | |
| Female | 20 (65) | 11 (35) | |
| Age (years) | < 0.001 | ||
| < 75 | 8 (28) | 21 (72) | |
| ≥ 75 | 14 (78) | 4 (22) | |
| Performance status | 0.03 | ||
| 0–1 | 12 (38) | 20 (62) | |
| 2–4 | 10 (67) | 5 (34) | |
| Smoking status | 0.024 | ||
| Current smoker | 3 (21) | 11 (79) | |
| Never or former light smoker | 19 (58) | 14 (42) | |
| Stage | 0.60 | ||
| Postoperative recurrence | 3 (50) | 3 (50) | |
| Stage IV | 19 (46) | 22 (54) | |
| Brain metastasis | 0.39 | ||
| Positive | 6 (38) | 10 (62) | |
| Negative | 16 (52) | 15 (48) | |
| EGFR genotype | 0.015 | ||
| Exon 19 deletion | 10 (34) | 20 (66) | |
| L858R | 12 (71) | 5 (29) | |
| Prior regimens | 0.25 | ||
| 1 | 11 (55) | 9 (45) | |
| ≥ 2 | 11 (41) | 16 (59) | |
BSA, body surface area.